<DOC>
	<DOCNO>NCT01183390</DOCNO>
	<brief_summary>The objective study evaluate comparative bioavailability Anastrozole 1 mg Tablets ( Teva Pharmaceuticals , USA ) ArimidexÂ® 1 mg Tablets ( AstraZeneca Pharmaceuticals LP , USA ) , single-dose healthy subject feed condition .</brief_summary>
	<brief_title>Anastrozole 1 mg Tablets Under Fed Conditions</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA Bioequivalence Statistical Methods</detailed_description>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>Healthy , nonsmoking , postmenopausal surgically sterile female subject 18 year age old . Body mass index 18 30 , inclusive . Indicate nonchild bearing status one follow criterion : Indication successful hysterectomy . No spontaneous menses least 1 year , must luteinizing hormone ( LH ) follicle stimulation hormone ( FSH ) level within postmenopausal range . Indication successful bilateral oophorectomy . Negative : HIV . Hepatitis B surface antigen Hepatitis C antibody . Urine drug abuse test ( marijuana , amphetamine , barbiturate , cocaine , opiates , benzodiazepine , methadone ) . Urine cotinine test . Serum pregnancy test . No significant diseases clinically significant finding physical examination . No clinically significant abnormal laboratory value . No clinically significant finding 12lead electrocardiogram ( ECG ) . No clinically significant finding vital sign measurement . Be informed nature study give write consent prior receive study procedure . Participants study unable child ( i.e . postmenopausal , hysterectomy ) . Known history presence clinically significant medical condition . Known suspected carcinoma . Known history presence : Hypersensitivity idiosyncratic reaction anastrozole and/or drug substance similar activity . Alcoholism within past 12 month . Drug dependence and/or substance abuse . Use tobacco nicotine containing product within last 6 month . Taken drug know induce inhibit hepatic drug metabolism 30 day prior dose . Taken hormone replacement therapy ( HRT ) 4 week prior dose . On special diet within 4 week prior drug administration ( e.g . liquid , protein , raw food diet ) . Participated another clinical trial receive investigational product within 30 day prior drug administration . Donated 250 mL blood within previous 30 day OR donate 251 500 mL blood previous 45 day OR donate 500 mL blood previous 56 day . Requirement nontopical medication ( prescription and/or overthecounter ) routine basis . Difficulty fast consume standard meal . Do tolerate venipuncture . Unable read sign Informed Consent Form .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>